OCS catalysts
Catalysts and events linked to OCS, newest first.
OCS stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Oculis to present Phase 2 ACUITY trial biomarker results at ACTRIMS-ECTRIMS 2026-10-20 · Up | clinical pipeline de-risking via plasma biomarker endpoints | Oculis scheduled presentation of Phase 2 ACUITY biomarker data at ACTRIMS-ECTRIMS on October 21-23. | Not recorded |
| Oculis Completes PREDICT-1 Registrational Randomization in Dry Eye Candidate 2026-10-19 · Up | clinical milestone derisking into registrational readout | Completed randomization of 176 patients in PREDICT-1 trial | Not recorded |
| Oculis to Present Licaminlimab Data Ahead of Year-End Registrational Readout 2026-10-07 · Up | biotech clinical pipeline de-risking ahead of Phase 3 topline readout | Oculis reiterated that PREDICT-1 registrational trial is on track for year-end readout. | Not recorded |
| Oculis presents dry eye candidate Licaminlimab ahead of year-end Phase 3 readout 2026-10-07 · Up | biotech pipeline valuation repricing on Phase 3 binary outcome timeline | PREDICT-1 registrational trial topline data scheduled for year-end 2026. | Not recorded |
| Oculis to Present Licaminlimab Data at AAO 2026 Ahead of PREDICT-1 Readout 2026-10-07 · Up | biotech registrational clinical trial readout milestones | Oculis announced AAO presentation and affirmed year-end PREDICT-1 trial readout. | Not recorded |
| Oculis to Present Licaminlimab at AAO 2026 Ahead of Year-End PREDICT-1 Readout 2026-10-07 · Up | biotech registrational trial catalyst progression | Oculis confirmed PREDICT-1 registrational trial topline readout on track for year-end 2026. | Not recorded |
| Oculis to Present Licaminlimab at Eyecelerator Ahead of Year-End PREDICT-1 Readout 2026-10-07 · Up | clinical pipeline milestone progress and trial catalyst timing | Oculis confirmed PREDICT-1 registrational readout around year-end 2026 ahead of Oct 8 presentation. | Not recorded |
| Oculis Schedules Licaminlimab Data at AAO Ahead of Year-End Registrational Readout 2026-10-07 · Watch | biopharma pipeline clinical event timeline | Oculis announced conference presentation date and year-end trial readout guidance. | Not recorded |
Do these developments change your position?
Review OCS alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-20Oculis to present Phase 2 ACUITY trial biomarker results at ACTRIMS-ECTRIMSOCS
- 2026-10-20Oculis to present Phase 2 ACUITY trial biomarker results at ACTRIMS-ECTRIMSOCS
- 2026-10-19Oculis Completes PREDICT-1 Registrational Randomization in Dry Eye CandidateOCS
- 2026-10-19Oculis Completes PREDICT-1 Registrational Randomization in Dry Eye CandidateOCS
- 2026-10-07Oculis to Present Licaminlimab Data Ahead of Year-End Registrational ReadoutOCS
- 2026-10-07Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 ReadoutOCS
- 2026-10-07Oculis presents dry eye candidate Licaminlimab ahead of year-end Phase 3 readoutOCS
- 2026-10-07Oculis to present Licaminlimab at AAO ahead of PREDICT-1 trial readout around year-endOCS
- 2026-10-07Oculis to Present Licaminlimab at AAO Ahead of Year-End PREDICT-1 ReadoutOCS
- 2026-10-07Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 ReadoutOCS
- 2026-10-07Oculis to Present Licaminlimab Data Ahead of Year-End Registrational ReadoutOCS
- 2026-10-07Oculis presents dry eye candidate Licaminlimab ahead of year-end Phase 3 readoutOCS
- 2026-10-07Oculis to Present Licaminlimab at AAO 2026 Ahead of Year-End PREDICT-1 ReadoutOCS
- 2026-10-07Oculis to Present Licaminlimab at Eyecelerator Ahead of Year-End PREDICT-1 ReadoutOCS
- 2026-10-07Oculis Schedules Licaminlimab Data at AAO Ahead of Year-End Registrational ReadoutOCS
- 2026-10-07Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 ReadoutOCS
- 2026-10-07Oculis to Present Licaminlimab Data at AAO 2026 Ahead of PREDICT-1 ReadoutOCS
- 2026-05-30Oculis eye drops fail Phase 3 primary endpoint for DME.OCS OCSAW
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.